A Study of NEOK002, an EGFR and MUC1 Targeting Bispecific ADC, in Participants With Select Solid Tumors
This is a first in human (FIH), Phase 1 dose escalation and expansion study in select solid tumors. This study includes 2 parts: a Dose Escalation and Backfill portion (Part A) and a Dose Expansion portion (Part B).
Participants must have locally advanced or metatstatic disease in a select tumor... [+4]
Participant's most recent systemic anti-cancer treatment was an ADC with a topoi... [+4]